NCCN Adds Neratinib to New Metastatic Breast Cancer Guidelines
In recommendations released January 27, 2023, the National Comprehensive Cancer Network (NCCN) now advises physicians
Neratinib
In recommendations released January 27, 2023, the National Comprehensive Cancer Network (NCCN) now advises physicians